Most medicines never reach their full potential

Absorption is where that potential is lost, and where Ibumix’s platform begins.

liquid crystal drug delivery, 
self-emulsifying drug delivery system (SEDDS), 
poorly soluble drug formulation,
oral drug delivery technologies,
pharmaceutical formulation platform, 
bioavailability enhancement technologies, 
lipid-based drug delivery systems,
advanced drug delivery systems

Absorption is the limiting factor

For many oral medicines, therapeutic performance is constrained by how effectively the active compound is delivered and absorbed.

Solubility, dissolution, and formulation all play a critical role in determining how much of a dose reaches systemic circulation.

Optimising these factors represents a significant opportunity to improve outcomes without changing the underlying molecule.


A formulation-first approach

Ibumix focuses on the physical and chemical environment in which a drug is delivered.

By engineering this environment, we can influence:

  • Dissolution behaviour
  • Absorption kinetics
  • Overall bioavailability

Technology Pillars

Advanced Formulation Engineering

Designing delivery systems that optimise how active compounds are presented and absorbed.

Established-Materials Advantage

Selecting excipient systems with an established, GRAS-status safety pedigree, de-risking the route a partner’s regulatory team already trusts.

Dissolution & Absorption Optimisation

Controlling how and when a drug becomes available for uptake.

Performance-Driven Design

Using data to iteratively refine formulation behaviour and outcomes.


From formulation to absorption

Formulation Design
Optimising composition and structure

Dissolution Behaviour
Controlling how the drug is released

Absorption Phase
Improving uptake into systemic circulation

Therapeutic Effect
Maximising effective dose delivery


Built for scale across medicines

The Ibumix approach is designed to be applied across multiple active pharmaceutical ingredients.

This creates a platform capability that extends beyond a single product, enabling:

  • Application across therapeutic areas
  • Adaptation to different molecular profiles
  • Integration into existing pharmaceutical pipelines

Structured scientific validation

Ibumix is advancing its technology through a structured research and development programme, including collaboration with a UK academic institution.

This enables:

  • Controlled experimental testing
  • High-quality analytical data generation
  • Independent validation of performance

Defensible by design

Ibumix is building a layered intellectual property strategy alongside its scientific development.

Four patent applications have been filed to date, protecting the platform’s core architecture and its extension into new chassis such as the bioavailability platform, with further filings planned as the platform grows.

This ensures that innovation is captured, protected, and positioned for long-term value creation.